766 related articles for article (PubMed ID: 9793187)
1. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
[TBL] [Abstract][Full Text] [Related]
2. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population.
Pajkrt E; Mol BW; van Lith JM; Bleker OP; Bilardo CM
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):156-62. PubMed ID: 9793186
[TBL] [Abstract][Full Text] [Related]
3. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
Thilaganathan B; Slack A; Wathen NC
Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
[TBL] [Abstract][Full Text] [Related]
4. Screening for chromosomal abnormalities in an unselected population by fetal nuchal translucency.
Hafner E; Schuchter K; Philipp K
Ultrasound Obstet Gynecol; 1995 Nov; 6(5):330-3. PubMed ID: 8590203
[TBL] [Abstract][Full Text] [Related]
5. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K; Nicolaides KH
BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
[TBL] [Abstract][Full Text] [Related]
6. First trimester nuchal translucency: effective routine screening for Down's syndrome.
Thilaganathan B; Sairam S; Michailidis G; Wathen NC
Br J Radiol; 1999 Oct; 72(862):946-8. PubMed ID: 10673944
[TBL] [Abstract][Full Text] [Related]
7. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia.
Zoppi MA; Ibba RM; Floris M; Monni G
Ultrasound Obstet Gynecol; 2001 Dec; 18(6):649-51. PubMed ID: 11844208
[TBL] [Abstract][Full Text] [Related]
8. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
9. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
[TBL] [Abstract][Full Text] [Related]
10. Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population.
Adekunle O; Gopee A; el-Sayed M; Thilaganathan B
Br J Radiol; 1999 May; 72(857):457-60. PubMed ID: 10505009
[TBL] [Abstract][Full Text] [Related]
11. Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland.
Gasiorek-Wiens A; Tercanli S; Kozlowski P; Kossakiewicz A; Minderer S; Meyberg H; Kamin G; Germer U; Bielicki M; Hackelöer BJ; Sarlay D; Kuhn P; Klapp J; Bahlmann F; Pruggmayer M; Schneider KT; Seefried W; Fritzer E; von Kaisenberg CS;
Ultrasound Obstet Gynecol; 2001 Dec; 18(6):645-8. PubMed ID: 11844207
[TBL] [Abstract][Full Text] [Related]
12. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population.
Schwärzler P; Carvalho JS; Senat MV; Masroor T; Campbell S; Ville Y
Br J Obstet Gynaecol; 1999 Oct; 106(10):1029-34. PubMed ID: 10519427
[TBL] [Abstract][Full Text] [Related]
13. [Screening for Down's syndrome at week 10-14 by measuring fetal nuchal translucency thickness].
Maymon R; Dreazen E; Weinraub Z; Bukovsky I; Herman A
Harefuah; 1999 Nov; 137(9):353-7, 432. PubMed ID: 11419032
[TBL] [Abstract][Full Text] [Related]
14. Increased nuchal translucency as a marker for fetal chromosomal defects.
Taipale P; Hiilesmaa V; Salonen R; Ylöstalo P
N Engl J Med; 1997 Dec; 337(23):1654-8. PubMed ID: 9385124
[TBL] [Abstract][Full Text] [Related]
15. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
[TBL] [Abstract][Full Text] [Related]
16. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
[TBL] [Abstract][Full Text] [Related]
17. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.
Snijders RJ; Noble P; Sebire N; Souka A; Nicolaides KH
Lancet; 1998 Aug; 352(9125):343-6. PubMed ID: 9717920
[TBL] [Abstract][Full Text] [Related]
18. The use of nuchal translucency measurement and second trimester biochemical markers in screening for Down's syndrome.
Michailidis GD; Spencer K; Economides DL
BJOG; 2001 Oct; 108(10):1047-52. PubMed ID: 11702836
[TBL] [Abstract][Full Text] [Related]
19. The implementation of first-trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units.
Pandya PP; Goldberg H; Walton B; Riddle A; Shelley S; Snijders RJ; Nicolaides KH
Ultrasound Obstet Gynecol; 1995 Jan; 5(1):20-5. PubMed ID: 7850584
[TBL] [Abstract][Full Text] [Related]
20. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population.
Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K
Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
